Britain and America have announced a major bilateral deal that will keep no duties on British drug products being sold in the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the NHS. This pledge guarantees that import taxes on these crucial goods will be held at nothing for a period of the next three years.
This deal follows earlier warnings to dramatically increase import taxes on patented pharmaceutical imports, with increases mentioned as high as 100%.
"This arrangement with the UK reinforces the global environment for new treatments and brings long-overdue equity to U.S.–U.K. drug exports," a statement said.
Trade Significance
Medicines constitute one of the Britain's largest exports to the United States, which is by far the largest destination for major British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to the third quarter, the UK sold drugs valued at billions to the US. This figure represented nearly one-fifth of British export trade in that timeframe.
"This deal protects jobs, boosts investment and facilitates the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Key British Pledges
The agreement entails several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to double overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to control costs will be restricted at 15%. In the past, refunds were more than twenty percent.
Broader Context
The deal takes place against a protracted row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were heightened by arguments that US patients were charged a premium for the equivalent treatments than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward American operations.
One official stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
